中心性浆液性脉络膜视网膜病变与年龄相关性黄斑变性的遗传位点重叠
该研究基于FinnGen、爱沙尼亚生物样本库及既往慢性CSC队列的遗传关联分析,共纳入1176例CSC患者和526787例对照。研究复制了CFH和GATA5附近的2个已知CSC风险位点,并新发现CD34/46、NOTCH4和PREX1附近的3个新位点;CFH和NOTCH4位点与AMD相关但方向相反。AMD多基因评分预测CSC风险降低(OR 0.76,95%CI 0.70-0.83,每增加1个标准差)。
要点
- 共识别5个CSC遗传风险位点:CFH、GATA5、CD34/46、NOTCH4和PREX1附近。
- CFH和NOTCH4位点与AMD相关,但效应方向与CSC相反。
- AMD多基因评分每增加1个标准差,CSC风险OR为0.76(95%CI 0.70-0.83)。
核心结论
- 在3个队列的遗传关联研究中识别出5个CSC遗传风险位点,提示脉络膜血管功能和补体调节相关基因可能发挥作用。
- 结果提示多基因AMD风险与CSC风险降低相关,且该遗传重叠主要归因于含补体基因的位点。
研究设计与样本
- 采用国际疾病分类第九版(ICD-9)和第十版(ICD-10)编码纳入和排除标准,在FinnGen研究和爱沙尼亚生物样本库(EstBB)中识别CSC患者和对照。
- Meta分析还纳入了既往报告的慢性CSC患者和对照。
- 在生物样本库队列中开展全基因组关联研究(GWAS),随后对所有队列进行Meta分析。
- 共纳入1176例CSC患者和526787例对照(女性312162例,占59.3%):FinnGen研究552例CSC患者和343461例对照,EstBB 103例CSC患者和178573例对照,Meta分析纳入521例慢性CSC患者和3577例对照。
- 数据于2022年3月1日至9月31日分析。
主要发现
- 复制了2个既往报告的CSC风险位点(CFH和GATA5附近),并识别出3个新位点(CD34/46、NOTCH4和PREX1附近)。
- CFH和NOTCH4位点与AMD相关,但方向相反。
- 优先基因在培养的脉络膜内皮细胞中表达增加,log2(每百万计数)中位数(IQR)为7.3(0.6)vs 其他基因4.7(3.7),P=0.004。
- 在单细胞RNA测序数据中,优先基因在脉络膜血管内皮细胞中差异表达,平均(SD)倍数变化为2.05(0.38)vs 其他细胞类型,P<7.1×10^-20。
- AMD多基因评分预测CSC风险降低(OR 0.76,95%CI 0.70-0.83,AMD-PGS每增加1个标准差,P=7.4×10^-10),该关联可能由含补体基因的位点介导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Central serous chorioretinopathy (CSC) is a serous maculopathy of unknown etiology. Two of 3 previously reported CSC genetic risk loci are also associated with AMD. Improved understanding of CSC genetics may broaden our understanding of this genetic overlap and unveil mechanisms in both diseases. OBJECTIVE: To identify novel genetic risk factors for CSC and compare genetic risk factors for CSC and AMD. DESIGN, SETTING, AND PARTICIPANTS: Using International Classification of Diseases, Ninth (ICD-9) and Tenth (ICD-10) Revision code-based inclusion and exclusion criteria, patients with CSC and controls were identified in both the FinnGen study and the Estonian Biobank (EstBB). Also included in a meta-analysis were previously reported patients with chronic CSC and controls. Data were analyzed from March 1 to September 31, 2022. MAIN OUTCOMES AND MEASURES: Genome-wide association studies (GWASs) were performed in the biobank-based cohorts followed by a meta-analysis of all cohorts. The expression of genes prioritized by the polygenic priority score and nearest-gene methods were assessed in cultured choroidal endothelial cells and public ocular single-cell RNA sequencing data sets. The predictive utility of polygenic scores (PGSs) for CSC and AMD were evaluated in the FinnGen study. RESULTS: A total of 1176 patients with CSC and 526 787 controls (312 162 female [59.3%]) were included in this analysis: 552 patients with CSC and 343 461 controls were identified in the FinnGen study, 103 patients with CSC and 178 573 controls were identified in the EstBB, and 521 patients with chronic CSC and 3577 controls were included in a meta-analysis. Two previously reported CSC risk loci were replicated (near CFH and GATA5) and 3 novel loci were identified (near CD34/46, NOTCH4, and PREX1). The CFH and NOTCH4 loci were associated with AMD but in the opposite direction. Prioritized genes showed increased expression in cultured choroidal endothelial cells compared with other genes in the loci (median [IQR] of log 2 [counts per million], 7.3 [0.6] vs 4.7 [3.7]; P = .004) and were differentially expressed in choroidal vascular endothelial cells in single-cell RNA sequencing data (mean [SD] fold change, 2.05 [0.38] compared with other cell types; P < 7.1 × 10-20). A PGS for AMD was predictive of reduced CSC risk (odds ratio, 0.76; 95% CI, 0.70-0.83 per +1 SD in AMD-PGS; P = 7.4 × 10-10). This association may have been mediated by loci containing complement genes. CONCLUSIONS AND RELEVANCE: In this 3-cohort genetic association study, 5 genetic risk loci for CSC were identified, highlighting a likely role for genes involved in choroidal vascular function and complement regulation. Results suggest that polygenic AMD risk was associated with reduced risk of CSC and that this genetic overlap was largely due to loci containing complement genes.
引用
- Rämö JT, Abner E, van Dijk EHC, et al. Overlap of Genetic Loci for Central Serous Chorioretinopathy With Age-Related Macular Degeneration. JAMA Ophthalmol. 2023. PMID: 37079300. doi:10.1001/jamaophthalmol.2023.0706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。